- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05217810
Un estudio de rPMS prospectivo, abierto, multicéntrico, de un solo brazo en un entorno real para Atectura® de 24 semanas
Un estudio prospectivo, de etiqueta abierta, multicéntrico, de un solo grupo de vigilancia posterior a la comercialización (rPMS) en un entorno del mundo real (obligatorio por la regulación local de HA) para Atectura® (QMF149 150/80 μg o.d., QMF149 150/ 160 μg al día y QMF149 150/320 μg al día a través de Breezhaler)
This surveillance was designed as a prospective, open-label, multicenter, single-arm, non-interventional, observational study to evaluate the safety and effectiveness of Atectura inhalation capsule for up to 24 weeks under routine clinical practice.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
The three different doses of Atectura inhalation capsule via Breezhaler will be prescribed according to the approved label information in Korea, and the investigation for any additional diagnostic or monitoring will be not conducted for this study
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Busan, Corea del Sur, 48108
- Novartis Investigative Site
-
Gyeongsangnam Do, Corea del Sur, 51353
- Novartis Investigative Site
-
Jeju City, Corea del Sur, 63241
- Novartis Investigative Site
-
Seoul, Corea del Sur, 05505
- Novartis Investigative Site
-
Seoul, Corea del Sur, 04763
- Novartis Investigative Site
-
Seoul, Corea del Sur, 06273
- Novartis Investigative Site
-
Seoul, Corea del Sur, 137 707
- Novartis Investigative Site
-
Taegu, Corea del Sur, 41944
- Novartis Investigative Site
-
Ulsan, Corea del Sur, 44033
- Novartis Investigative Site
-
-
Dalseo gu
-
Daegu, Dalseo gu, Corea del Sur, 42602
- Novartis Investigative Site
-
-
Gangneung si
-
Kangwon Do, Gangneung si, Corea del Sur, 210 711
- Novartis Investigative Site
-
-
Gangwon-do
-
Wŏnju, Gangwon-do, Corea del Sur, 26426
- Novartis Investigative Site
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Corea del Sur, 10380
- Novartis Investigative Site
-
Guri-si, Gyeonggi-do, Corea del Sur, 11923
- Novartis Investigative Site
-
-
Gyeongsangnam-do
-
Jinju, Gyeongsangnam-do, Corea del Sur, 52727
- Novartis Investigative Site
-
-
Jeollabuk-do
-
Jeonju, Jeollabuk-do, Corea del Sur, 54907
- Novartis Investigative Site
-
-
Jeonlabuk Do
-
Iksan Si, Jeonlabuk Do, Corea del Sur, 54538
- Novartis Investigative Site
-
-
Korea
-
Daejeon, Korea, Corea del Sur, 35015
- Novartis Investigative Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
subjects who received at least one dose of Atectura inhalation capsule via Breezhaler and that have provided consent for their data collection.
Descripción
Inclusion Criteria:
- Adolescent (≥12 years of age) and adult patients with a physician's diagnosis of asthma, who are prescribed Atectura inhalation capsule (indacaterol acetate/mometasone furoate; 150/80, 150/160, 150/320 μg) via Breezhaler, as per the approved label information
- Patients who participate in the study after signing the consent form for data collection and use (Data Privacy ICF) after receiving a clear explanation of the objectives and nature of the study from the investigator (For patients under the age of 18, consent and signature of a legal representative is required)
Exclusion Criteria:
- Patients who are contraindicated for this medicinal product as described in the Precautions for Use in the label information (package insert) A. Patients with hypersensitivity reaction to this medicinal product or any of its constituents B. Because this medicinal product contains lactose, patients with hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption, etc.
- Patients with acute asthma symptoms, including acute episodes of bronchospasm, for which a short-acting bronchodilator is required
- Patients participating in other interventional clinical trials
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Atectura inhalation capsule (150/80ug)
Indacaterol acetate/Mometasone furoate; 150/80ug |
There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled. |
|
Atectura inhalation capsule (150/160ug)
Indacaterol acetate/Mometasone furoate; 150/160ug |
There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled. |
|
Atectura inhalation capsule (150/320ug)
Indacaterol acetate/Mometasone furoate; 150/320ug |
There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of adverse events and serious adverse events
Periodo de tiempo: 24 weeks
|
Incidence of AE and SAE will be collected |
24 weeks
|
|
Incidence of unexpected adverse events and unexpected serious adverse events
Periodo de tiempo: 24 weeks
|
Incidence of unexpected AE and SAE will be collected. The term "unexpected" means not listed in local label |
24 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
change from baseline in trough FEV1
Periodo de tiempo: Baseline, week 12
|
Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. |
Baseline, week 12
|
|
change from baseline in ACT score
Periodo de tiempo: Baseline, week 12
|
The Asthma Control Test (ACT) is a validated tool to assess overall asthma control. It is a 1 page questionnaire consisting of 5 simple questions assessing: asthma symptoms, use of rescue medications, and the impact of asthma on everyday functioning. All questions are scored on a 5-point Likert scale, with a higher score indicating better control. All scores are added together to calculate a total score. Total score ranges from 5 to 25. A positive change indicates improvement. |
Baseline, week 12
|
|
Effective rate and ineffective rate by investigator assessment
Periodo de tiempo: week 12
|
Effective (improved) rate and ineffective (unchanged/aggravated) rate by investigator assessment |
week 12
|
|
Baseline characteristics of patients showing adverse events/adverse drug reactions
Periodo de tiempo: 24 weeks
|
The incidence rates of AEs/ADRs will be presented by factors, such as subject baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. above 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations. |
24 weeks
|
|
Baseline characteristics of patient in relation to changes from baseline through FEV1 and ACT score
Periodo de tiempo: 12 weeks
|
Regression analysis will be performed to determine factors affecting the change in trough FEV1 and ACT score, out of baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations |
12 weeks
|
|
Baseline characteristics of patients in relation to the investigator assessment
Periodo de tiempo: 12 weeks
|
Logistic regression analysis will be performed to determine factors affecting the effectiveness (improved) in the investigator assessment, out of baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. above 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations. |
12 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CQMF149EKR01
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .